Asthma is one of China’s most common respiratory diseases, affecting millions of people. FeNo testing aids in the treatment and diagnosis of asthma diseases. Furthermore, asthma is one of the most common chronic airway diseases in both children and adults in China. The Chinese government is working to raise public awareness about asthma disease control and improve diagnostic procedures, which will provide opportunities in the China FeNo testing market.
Request For a Sample Copy of This Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=china-feno-testing-market
Data Bridge Market Research analyses that the FeNO testing market, which was USD 23,499.05 million in 2022, is expected to reach USD 66,564.09 million by 2030, at a CAGR of 13.9% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
A FeNO test or exhaled nitric oxide test can be used to determine how much lung inflammation is present and how well inhaled steroids are suppressing this inflammation in patients with allergic or eosinophilic asthma. FeNO testing is a quantitative, non-invasive, simple, and safe test that can be performed in primary care by a properly trained health care professional who is competent to deliver and interpret the results. The advantages of FeNO testing in primary care are patients are not required to be referred to a secondary care facility for additional testing and when combined with respiratory symptoms and lung function tests that are suggestive of asthma, a positive FeNO test supports a diagnosis.
Strategic business expansion activities by major players to increase revenue share and product portfolio by launching innovative products are positively impacting the growth of the FeNO testing market. Caire Inc, a medical device manufacturer, acquired Spirosure Inc in 2020. The acquisition will allow Spirosure’s technology to be applied to the company’s market-leading oxygen solution portfolio. This acquisition is expected to help the company improve its operations and increase its revenue share.
The China FeNO testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for FeNO testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the FeNO testing market. The data is available for historic period 2011-2021.
Key players operating in the China FeNO Testing Market include:
Bedfont Scientific Ltd. (U.K.), Spirosure, Inc (U.S.), Medisoft Limited (Belgium), Bosch Healthcare Solutions GmbH (A Subsidiary of Robert Bosch GmbH) (Germany), Sunvou (China), RuiBreath (China), Circassia (U.K.), ECO MEDICS AG (Switzerland)
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475